Gardiquimod (hydrochloride)

Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs) . Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM[1][2].

Product Specifications

CAS Number

[2956183-81-4]

UNSPSC

12352005

Target

HIV; Toll-like Receptor (TLR)

Related Pathways

Anti-infection; Immunology/Inflammation

Field of Research

Cancer; Infection

Smiles

OC(C)(CN1C(CNCC)=NC2=C1C3=C(C=CC=C3)N=C2N)C.Cl

Molecular Formula

C17H24ClN5O

Molecular Weight

349.86

References & Citations

[1]Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29 (6) :907-18.|[2]Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369 (2) :298-306.